Quince Therapeutics Statistics
Total Valuation
QNCX has a market cap or net worth of $66.21 million. The enterprise value is $21.58 million.
Important Dates
The next estimated earnings date is Tuesday, November 12, 2024, after market close.
| Earnings Date | Nov 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
QNCX has 43.28 million shares outstanding. The number of shares has increased by 14.07% in one year.
| Shares Outstanding | 43.28M |
| Shares Change (YoY) | +14.07% |
| Shares Change (QoQ) | +0.20% |
| Owned by Insiders (%) | 13.77% |
| Owned by Institutions (%) | 19.01% |
| Float | 34.60M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.42 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.15, with a Debt / Equity ratio of 0.31.
| Current Ratio | 6.15 |
| Quick Ratio | 5.85 |
| Debt / Equity | 0.31 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -79.38% and return on invested capital (ROIC) is -24.87%.
| Return on Equity (ROE) | -79.38% |
| Return on Assets (ROA) | -16.50% |
| Return on Capital (ROIC) | -24.87% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.66M |
| Employee Count | 32 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, QNCX has paid $118,000 in taxes.
| Income Tax | 118,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +62.06% in the last 52 weeks. The beta is 0.71, so QNCX's price volatility has been lower than the market average.
| Beta (5Y) | 0.71 |
| 52-Week Price Change | +62.06% |
| 50-Day Moving Average | 0.84 |
| 200-Day Moving Average | 0.93 |
| Relative Strength Index (RSI) | 74.10 |
| Average Volume (20 Days) | 1,274,873 |
Short Selling Information
The latest short interest is 1.91 million, so 4.42% of the outstanding shares have been sold short.
| Short Interest | 1.91M |
| Short Previous Month | 1.92M |
| Short % of Shares Out | 4.42% |
| Short % of Float | 5.52% |
| Short Ratio (days to cover) | 30.08 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -29.52M |
| Pretax Income | -30.20M |
| Net Income | -53.12M |
| EBITDA | -29.13M |
| EBIT | -29.52M |
| Earnings Per Share (EPS) | -$1.30 |
Full Income StatementBalance Sheet
The company has $59.45 million in cash and $14.38 million in debt, giving a net cash position of $45.06 million or $1.04 per share.
| Cash & Cash Equivalents | 59.45M |
| Total Debt | 14.38M |
| Net Cash | 45.06M |
| Net Cash Per Share | $1.04 |
| Equity (Book Value) | 46.97M |
| Book Value Per Share | 1.09 |
| Working Capital | 53.12M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$27.99 million and capital expenditures -$102,000, giving a free cash flow of -$28.09 million.
| Operating Cash Flow | -27.99M |
| Capital Expenditures | -102,000 |
| Free Cash Flow | -28.09M |
| FCF Per Share | -$0.65 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |